PhRMA vs. CMS' GLOBE: The New Medicare Part B Drug Pricing Fight

This episode is brought to you by Semafor Healthcare.

Delivered weekly from David Lim, Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape. Subscribe for free.

How far can international reference pricing go in lowering prescription drug costs?

Health Affairs Publishing's Jeff Byers welcomes Senior Editor Michael Gerber back to the pod to discuss the finalized GLOBE model for Medicare Part B drugs, the administration’s broader "most favored nation" strategy, the PhRMA lawsuit against CMS over the model, and what policy watchers should monitor in the months ahead.

Join Health Affairs Publishing on November 17 for an exclusive event with Jetson Leder-Luis, PhD of Boston University getting Insiders up to speed on fraud policies and what to watch in the health care industry moving forward.

Related Links:

• Health Affairs Moves Exclusively Online (Health Affairs Forefront)
• CMS Finalizes New Mandatory Drug Payment Model to Deliver Lower Drug Prices for Beneficiaries in Original Medicare Part B
• Administration Finalizes Medicare Part B International Reference Pricing Model (Health Affairs Forefront)
• PhRMA Challenges CMS’ MFN Policy as Unlawful Overreach (PhRMA)

Sign up for Health Affairs' free newsletter to catch up on our new articles, podcasts, and events.

Subscribe to Semafor Healthcare for free.